# HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

> **NCT05176691** · PHASE1 · WITHDRAWN · sponsor: **Hutchmed**

## Conditions studied

- CLL/SLL
- NHL
- MCL
- MZL
- Lymphoplasmacytic Lymphoma
- Waldenstrom Macroglobulinemia
- Follicular Lymphoma
- DLBCL
- Richter Syndrome

## Interventions

- **DRUG:** HMPL-760

## Key facts

- **NCT ID:** NCT05176691
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-02-15
- **Primary completion:** 2022-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** HUTCHMED has decided to discontinue the HMPL 760 study.
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176691, "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05176691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*